Journal
MOLECULAR THERAPY
Volume 24, Issue 3, Pages 458-464Publisher
CELL PRESS
DOI: 10.1038/mt.2015.151
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [R01EY022975]
Ask authors/readers for more resources
In addition to their broad potential for therapeutic gene delivery, adeno-associated virus (AAV) vectors possess the innate ability to stimulate homologous recombination in mammalian cells at high efficiencies. This process referred to as AAV-mediated gene targeting has enabled the introduction of a diverse array of genomic modifications both in vitro and in vivo. With the recent emergence of targeted nucleases, AAV-mediated genome engineering is poised for clinical translation. Here, we review key properties of AAV vectors that underscore its unique utility in genome editing. We highlight the broad range of genome engineering applications facilitated by this technology and discuss the strong potential for unifying AAV with targeted nucleases for next-generation gene therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available